Saxenda® (liraglutide) injection 3 mg becomes the first FDA-approved therapy to treat obesity in adolescents in more than a decade PLAINSBORO, N.J., Dec. 4, 2020 /PRNewswire/ -- Novo Nordisk today ...

The GLP-1 receptor agonist, which was first approved for adults in December 2014, is now a treatment option for adolescents with obesity ages 12-17 as adjunct to diet and exercise. More specifically, ...

Saxenda Approved for Weight Management The FDA has approved Saxenda (liraglutide [rDNA origin]) injection for chronic weight management. Saxenda is the first glucagon-like peptide-1 (GLP-1) receptor ...

Novo Nordisk A/S (NVO) announced that the FDA has approved an updated label for Saxenda (liraglutide) injection 3 mg. The Saxenda Injection is now approved for the treatment of obesity in adolescents ...

Saxenda (liraglutide) and Ozempic (semaglutide) are brand-name solutions for subcutaneous injection. Saxenda is approved for weight management. Doctors may prescribe Ozempic off-label for this purpose ...

The FDA has approved Saxenda® (liraglutide; Novo Nordisk) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in patients aged 12 years and older with ...

Saxenda (liraglutide) is a prescription drug that’s used for weight management. Saxenda’s cost may depend on factors such as whether you have health insurance and the pharmacy you use. Saxenda is used ...

Saxenda (liraglutide) is a prescription-only injectable medication in the same class as Ozempic (semaglutide). However, unlike Ozempic, Saxenda is approved by the Food and Drug Administration (FDA) ...

Saxenda (liraglutide) is a brand-name drug prescribed for weight management in adults and some children. Saxenda comes as an injection pen that’s typically used once per day. Your doctor will ...